A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

NCT03332017 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

217

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Follicular Non-Hodgkin Lymphoma

Interventions

DRUG: Zanubrutinib
DRUG: Obinutuzumab

Sponsor

BeiGene